ReviewPLoS medicine2019
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
Review in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Factors associated with screening failure and study withdrawal in multidrug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Trial
- Incorporating estimands into clinical trial statistical analysis plans.Clinical trials (London, England) · 2022Trial
- Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.BMC infectious diseases · 2022Trial
- Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.PloS one · 2022Trial
- Guiding principles for pragmatic randomised trials of tuberculosis treatments.The Lancet. Infectious diseases · 2026Review
- Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization.BMC medical research methodology · 2025Article
- Drug-resistant tuberculosis treatments, the case for a phase III platform trial.Bulletin of the World Health Organization · 2024Article
- Article
- A comparison of clinical development pathways to advance tuberculosis regimen development.BMC infectious diseases · 2022Article
- Rethinking intercurrent events in defining estimands for tuberculosis trials.Clinical trials (London, England) · 2022Article
- Article
- A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.Statistics in medicine · 2021Article
- Advances in clinical trial design: Weaving tomorrow's TB treatments.PLoS medicine · 2020Review
- Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.PLoS medicine · 2019Review
- Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.PLoS medicine · 2019Article
- Advances in clinical trial design for development of new TB treatments: A call for innovation.PLoS medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In a Collection Review, Patrick Phillips and colleagues discuss developments in clinical trial design for the evaluation of TB therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.